Home » Isotechnika Completes Carcinogenicity Study
Isotechnika Completes Carcinogenicity Study
Canadian drugmaker Isotechnika has finished a rat carcinogenicity study for its lead immunosuppressive drug ISA247.
The drug did not exhibit any carcinogenicity up to the highest doses tested in male and female rats over a two-year period, according to Isotechnika.
Carcinogenicity studies are required by the FDA and other regulatory authorities and are a part of the package submitted for marketing approval.
ISA247 is undergoing a Phase IIb trial in the U.S. for the prevention of kidney graft rejection and a Phase III European/Canadian trial in psoriasis patients.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May